Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics

Many of Poorly aqueous soluble drugs including antihypertensive agents, antidiabetic agents and anti cancer agents require novel delivery technologies that will enhance their GIT absorption, maximize their bioavailability and lead to efficient therapeutic effect. Over the past two decades, there has been a steady rise in the number of commercially available nanoparticle (NP), solid nanodispersion and solid lipid nanoparticles (SLNs) therapeutics as novel delivery technologies intended to enhance the GIT absorption, maximize the bioavailability and lead to efficient therapeutic effect of poorly aqueous soluble drugs. Glimepiride is considered as new generation of sulfonyl urea and administered orally. Its main draw back is its poor solubility. Glimepiride, chemically described as 1-[[4-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1- carboxamide) ethyl] phenyl] sulphonyl] -3-(trans-4-methylcyclohexyil) urea, is water insoluble oral antidiabetic drug from the sulfonylurea class, which is widely used in the treatment of type 2 diabetes. Glimepiride was selected as drug candidate, as it is not available in such dosage forms and thus, to enhance safety and efficacy of Glimepiride, achieve better compliance, solve the problem of solubility, absorption and bioavailability. To achieve these goals, the work in our thesis is divided into four chapters

Issued also as CD